Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Oncoletter provides you with quotes from the abstract's conclusions. To see more, go the ASCO Meeting Library while clicking on the link of the study-titles (to see videos and slides needs a payable registration)
The abstract concludes:
Read the comment in the ASCO DAILY NEWS:
CCO Independent Conference Coverage of the 2020 ASCO Virtual Scientific Meeting:
————————————————————————————————————————————————————————————————————————————
The abstract concludes:
The addition of tras/per to perioperative FLOT significantly improved pCR and nodal negativity rates in pts with Her2+ resectable esophagogastric adenocarcinoma at the price of higher rates of diarrhea and leukopenia. Clinical trial information:
NCT02581462.
————————————————————————————————————————————————————————————————————————————
This long-term analysis found that second-line pembrolizumab prolonged OS among patients with PD-L1–positive GC and led to fewer drug-related AEs vs paclitaxel. Clinical trial information:
NCT02370498.
————————————————————————————————————————————————————————————————————————————
We have demonstrated: 1) two-year OS of 41.6% (median 22.4 months) with mFOLFIRINOX and 48.8% (median 23.6 months) with Gem/nabP for all eligible pts starting treatment for resectable PDA; 2) post-resection DFS of 10.9 months and 14.2 months, respectively; 3) adequate safety and high resectability rates with peri-op CTx; 4) little evidence that either regimen improves OS compared with the historical standard. Clinical trial information:
NCT02562716.
————————————————————————————————————————————————————————————————————————————
The abstract concludes:
There was no difference in resection rate between arms, however neoadjuvant therapy had a significant survival benefit compared with immediate surgery. Clinical trial information: 89500674.
————————————————————————————————————————————————————————————————————————————
The abstract concludes:
Donafenib significantly improves OS over sorafenib with favourable safety and tolerability. Donafenib is a promising superior first-line therapy for advanced HCC. Funding: Zelgen. Clinical trial information:
NCT02645981.
————————————————————————————————————————————————————————————————————————————
Apatinib significantly prolonged OS and PFS in Chinese pts with pretreated advanced HCC, and was well tolerated with a manageable safety profile. Clinical trial information:
NCT02329860.
————————————————————————————————————————————————————————————————————————————
The abstract concludes:
————————————————————————————————————————————————————————————————————————————
Ramon Jin, Haeseong Park, Andrea Wang-Gillam, et al.
The abstract concludes:
FOLFIRINOX is a highly effective three-drug regimen for first-line treatment of advanced gastroesophageal cancer with expected, tolerable toxicities. Clinical trial information:
NCT01928290.
Published simultaneously in JAMA Oncology:
————————————————————————————————————————————————————————————————————————————
Zev A. Wainberg, Tanios S. Bekaii-Saab, Richard Hubner, et al.
- The primary endpoint is overall survival (OS).
- Secondary endpoints (progression-free survival [PFS] and overall response rate assessed with Response Evaluation Criteria in Solid Tumors v1.1 criteria) will be compared only if the primary endpoint shows superiority for liposomal irinotecan + 5-FU/ LV + OX over nab-paclitaxel + gemcitabine.
————————————————————————————————————————————————————————————————————————————
Esther Pijnappel, Judith de Vos-Geelen, Teresa Macarulla Mercade, et al.
Andrew Eugene Hendifar, Sungjin Kim, Mourad Tighiouart, et al.
The abstract concludes:
Bermekimab, nano-liposomal irinotecan and 5-fluorouracil in refractory pancreatic cancer patients with cachexia was well-tolerated with promising efficacy and improvements in patient performance. Clinical trial information:
NCT03207724.
————————————————————————————————————————————————————————————————————————————
Kohei Shitara, Yung-Jue Bang, Satoru Iwasa, et al.
The abstract concludes:
T-DXd demonstrated statistically significant and clinically meaningful improvements in ORR and OS compared with standard chemotherapy (paclitaxel or irinotecan) in patients with HER2+ advanced gastric or GEJ adenocarcinoma. Clinical trial information:
NCT03329690.
view slide set
————————————————————————————————————————————————————————————————————————————
MORE ABSTRACTS:
Poster Discussion Session
Poster Session
ASCO Direct™ Focus – ASCO®20 Virtual Program Top presentations and expert interviews now available on demand! Visit ascodirect2020.com and enter the following username „asco“ and password: „oncology" ASCO Direct Focus is an officially licensed online program for oncology professionals worldwide, providing complimentary access to an ASCO-curated selection of top presentations from the ASCO20 Virtual Scientific Program, plus expert commentaries. Gastrointestinal (Abstracts #4500, 4504, 4508) Access Content Now |
|
|